MiNA Therapeutics Announces Presentation Of Pre-Clinical Data Supporting On-Target Mechanism Of Action Of Clinical Candidate MTL-CEBPA

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of data supporting the on-target mechanism of action of drug candidate MTL-CEBPA. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a Phase I clinical study in patients with liver cancer.

Back to news